The anti-aging biotech has secured one of the year’s biggest venture fundings to bring its first drug into testing. Elsewhere, Lilly nabbed a “GLP-2” obesity drug and Praxis shares tumbled.
An article from
News roundup
The anti-aging biotech has secured one of the year’s biggest venture fundings to bring its first drug into testing. Elsewhere, Lilly nabbed a “GLP-2” obesity drug and Praxis shares tumbled.
Published June 3, 2026
Getty Images
NewLimit raises $435M Series C, valuation hits $3.1B
Longevity startup NewLimit raises $435 million ahead of first clinical trial
Anti-aging startup NewLimit raises $435M at $3B+ valuation, eyes clinic in 2027
Legend Biotech emerged as a rare market winner
NewLimit triples valuation to $3B with $435M funding round
Post-Hoc: The world's biggest drugmaker get more secretive
Eli Lilly Deepens Innovation Push Through New Biopharma Collaborations - Eli Lilly (NYSE:LLY)
Club name Eli Lilly made its third deal of the year to acquire an attractive experimental drug.
The South San Francisco biotech plans to begin its first human trial of a liver cell-reprogramming therapy next year
The drugmaker announced it will buy three privately held vaccine makers in deals worth almost $4 billion combined.
Longevity startup NewLimit plans to launch its first clinical trial of a liver medicine after raising a staggering $435 million…
NewLimit said Tuesday it has raised a $435 million Series C round at a $3.1 billion post-money valuation.
Lilly shares rose more than 4% Monday, while rival Novo Nordisk tanked.
